Open Actively Recruiting

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

About

Brief Summary

IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.

Primary Purpose
Treatment
Study Type
Interventional
Phase
Phase 1

Eligibility

Gender
Female
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

Inclusion Criteria:

Exclusion Criteria:

Join this Trial

Share:
Study Stats
Protocol No.
22-001780
Category
Cervical Cancer
Colorectal Cancer
Other Cancer
Ovarian Cancer
Location
  • UCLA Westwood
For Providers
NCT No.
NCT05527184
For detailed technical eligibility, visit ClinicalTrials.gov.